TR - Trillium Therapeutics Stock Price, News & Analysis

C$14.61 1.26 (9.44 %)
(As of 11/22/2017 04:00 PM ET)
Previous CloseC$14.61
Today's RangeC$13.37 - C$14.94
52-Week RangeC$5.11 - C$14.94
Volume60,745 shs
Average Volume22,503 shs
Market CapitalizationC$157.71 million
P/E RatioN/A
Dividend YieldN/A
Beta0.54

About Trillium Therapeutics (TSE:TR)

Trillium Therapeutics logoTrillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:TR
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPSC($5.07)
Net IncomeN/A
Net MarginsN/A
Return on Equity-246.11%
Return on Assets-64.76%

Miscellaneous

EmployeesN/A
Outstanding Shares10,790,000

Frequently Asked Questions for Trillium Therapeutics (TSE:TR)

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TR."

When will Trillium Therapeutics make its next earnings announcement?

Trillium Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March, 9th 2018. View Earnings Estimates for Trillium Therapeutics.

Who are some of Trillium Therapeutics' key competitors?

Who are Trillium Therapeutics' key executives?

Trillium Therapeutics' management team includes the folowing people:

  • Calvin R. Stiller M.D., Independent Chairman of the Board
  • Niclas Stiernholm, President, Chief Executive Officer, Director
  • James T. Parsons, Chief Financial Officer
  • Malik Slassi, Senior Vice President - Discovery Research
  • Robert Uger, Chief Scientific Officer
  • Scott Duncan, Director of Intellectual Property
  • Penka Petrova, Chief Development Officer
  • Eric L Sievers, Chief Medical Officer
  • Luke M. Beshar CPA, Independent Director (Age 58)
  • Henry Friesen M.D., Independent Director (Age 79)

How do I buy Trillium Therapeutics stock?

Shares of Trillium Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Trillium Therapeutics' stock price today?

One share of Trillium Therapeutics stock can currently be purchased for approximately C$14.61.

How big of a company is Trillium Therapeutics?

Trillium Therapeutics has a market capitalization of C$157.71 million.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.


MarketBeat Community Rating for Trillium Therapeutics (TR)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  23 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  46
MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Trillium Therapeutics (TSE:TR)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Trillium Therapeutics (TSE:TR)

Price Target History for Trillium Therapeutics (TSE:TR)

Analysts' Ratings History for Trillium Therapeutics (TSE:TR)

Show:
DateFirmActionRatingPrice TargetDetails
7/17/2017HC WainwrightReiterated RatingBuyView Rating Details
5/12/2017Leerink SwannReiterated RatingOutperformView Rating Details
11/4/2016Bloom BurtonReiterated RatingBuyView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History for Trillium Therapeutics (TSE:TR)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Trillium Therapeutics (TSE:TR)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Trillium Therapeutics (TSE:TR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Trillium Therapeutics (TSE TR)

Insider Trades by Quarter for Trillium Therapeutics (TSE:TR)

Insider Trades by Quarter for Trillium Therapeutics (TSE TR)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/22/2016Calvin R StillerDirectorBuy9,000C$11.11C$100,026.00
3/21/2016Eric L SieversInsiderBuy23,020C$8.21C$188,994.20
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Trillium Therapeutics (TSE TR)

Source:
DateHeadline
BRIEF-Trillium announces private placement to fund development of cancer drugsBRIEF-Trillium announces private placement to fund development of cancer drugs
www.reuters.com - November 15 at 4:37 PM
BRIEF-Trillium Therapeutics reports Q3 resultsBRIEF-Trillium Therapeutics reports Q3 results
www.reuters.com - November 10 at 8:56 AM
Trillium Therapeutics: The Story Keeps Getting BetterTrillium Therapeutics: The Story Keeps Getting Better
seekingalpha.com - November 6 at 8:18 AM
Trillium Therapeutics (TRIL) Appoints Helen Tayton-Martin to Board - StreetInsider.comTrillium Therapeutics (TRIL) Appoints Helen Tayton-Martin to Board - StreetInsider.com
www.streetinsider.com - October 13 at 9:23 AM
Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual MeetingTrillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting
finance.yahoo.com - October 6 at 11:40 AM
Trillium Therapeutics, Inc. :TR-CA: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016Trillium Therapeutics, Inc. :TR-CA: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016
finance.yahoo.com - October 6 at 11:40 AM
Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor TrialTrillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial
finance.yahoo.com - October 6 at 11:40 AM
Trillium reports 2Q lossTrillium reports 2Q loss
www.cnbc.com - August 11 at 8:52 AM
Trillium reports 2Q lossTrillium reports 2Q loss
www.cnbc.com - August 11 at 8:52 AM
Trillium Therapeutics Inc (TR) Set to Announce Quarterly Earnings on ThursdayTrillium Therapeutics Inc (TR) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - August 3 at 7:10 AM
Trillium Therapeutics (TRIL) Announces Expansion of Clinical Trial With TTI-621 to Include Combination with PD-1 ... - StreetInsider.comTrillium Therapeutics (TRIL) Announces Expansion of Clinical Trial With TTI-621 to Include Combination with PD-1 ... - StreetInsider.com
www.streetinsider.com - June 8 at 3:59 PM
BRIEF-Cormorant Asset Management reports 5.66 pct passive stake in Trillium TherapeuticsBRIEF-Cormorant Asset Management reports 5.66 pct passive stake in Trillium Therapeutics
www.reuters.com - June 5 at 10:44 PM
Trillium Therapeutics (TRIL) to Present on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCOTrillium Therapeutics (TRIL) to Present on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO
www.streetinsider.com - June 2 at 2:27 AM
IIROC Trade Resumption - TRILIIROC Trade Resumption - TRIL
www.bizjournals.com - May 27 at 6:21 AM
BRIEF-Trillium announces pricing of U.S.$30.0 mln public offering of common sharesBRIEF-Trillium announces pricing of U.S.$30.0 mln public offering of common shares
www.reuters.com - May 27 at 6:21 AM
Relative Strength Alert For Trillium Therapeutics (TRIL)Relative Strength Alert For Trillium Therapeutics (TRIL)
www.thestreet.com - May 26 at 7:51 AM
BRIEF-Trillium Therapeutics offers shares in public offeringBRIEF-Trillium Therapeutics offers shares in public offering
www.reuters.com - May 26 at 7:51 AM
BRIEF-Trillium Therapeutics says TTI-621 program momentum continues in 2017 - ReutersBRIEF-Trillium Therapeutics says TTI-621 program momentum continues in 2017 - Reuters
www.reuters.com - March 11 at 7:49 AM
BRIEF-Trillium Therapeutics provides additional details on TTI-621BRIEF-Trillium Therapeutics provides additional details on TTI-621
www.reuters.com - February 25 at 3:50 AM
Form 6-K Trillium Therapeutics For: Feb 07 - StreetInsider.comForm 6-K Trillium Therapeutics For: Feb 07 - StreetInsider.com
www.streetinsider.com - February 8 at 8:05 AM
Trillium Therapeutics Inc. - MarketWatchTrillium Therapeutics Inc. - MarketWatch
www.marketwatch.com - February 4 at 9:46 PM
BRIEF-Trillium Therapeutics Inc intends to provide an update on ongoing TTI-621 trials - ReutersBRIEF-Trillium Therapeutics Inc intends to provide an update on ongoing TTI-621 trials - Reuters
www.reuters.com - February 4 at 9:46 PM
Trillium Therapeutics (TRIL) Announces Presentation of Initial TTI ... - StreetInsider.comTrillium Therapeutics (TRIL) Announces Presentation of Initial TTI ... - StreetInsider.com
www.streetinsider.com - December 5 at 8:36 AM
Trillium Therapeutics (TRIL) Approved by FDA to Commence TTI-621 Phase 1 in olid Tumors and Mycosis FungoidesTrillium Therapeutics (TRIL) Approved by FDA to Commence TTI-621 Phase 1 in olid Tumors and Mycosis Fungoides
www.streetinsider.com - August 18 at 10:56 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Trillium Therapeutics (TSE TR) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.